skip to main content
Give

Clifford Stephan, PhD

Clifford Stephan
Clifford Stephan, PhD

Research Associate Professor

Director, High Throughput Research and Screening Center

Director, Micro-physiological Lead Optimization and Toxicity Screening Center

Contact

Center for Translational Cancer Research
2121 W. Holcombe Blvd, Rm 907
Houston, TX 77030
cstephan@tamu.edu
Phone: 713.677.7456
Fax: 713.677.7779
Stephan Lab
High Throughput Research and Screening Center
Micro-physiological Lead Optimization and Toxicity Screening (MLOTS)

Biography

Education and Training

  • Ph.D., Pharmacology, Vanderbilt University
  • B.A., Chemistry & Molecular Biology, Vanderbilt University
  • Postdoctoral Training Brigham and Women’s Hospital, Harvard Medical School

Research Interests

  • Drug Discovery
  • High Throughput Drug Screening
  • Combinatorial Drug Screening

Selected Publications

  1. Yu W, Chen Y, Putluri N, Osman A, Coarfa C, Putluri V, Kamal AHM, Asmussen JK, Katsonis P, Myers JN, Lai SY, Lu W, Stephan CC, Powell RT, Johnson FM, Skinner HD, Kazi J, Ahmed KM, Hu L, Threet A, Meyer MD, Bankson JA, Wang T, Davis J, Parker KR, Harris MA, Baek ML, Echeverria GV, Qi X, Wang J, Frederick AI, Walsh AJ, Lichtarge O, Frederick MJ, Sandulache VC. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. Br J Cancer. 2023 Jun;128(11):2013-2024. doi: 10.1038/s41416-023-02253-7. Epub 2023 Apr 3. PubMed PMID: 37012319; PubMed Central PMCID: PMC10205814. 
  2. Fan F, Ghosh S, Powell R, Roszik J, Park Y, Sobieski M, Sorokin A, Stephan C, Kopetz S, Ellis LM, Bhattacharya R. Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. PLoS One. 2023;18(3):e0281063. doi: 10.1371/journal.pone.0281063. eCollection 2023. PubMed PMID: 36952536; PubMed Central PMCID: PMC10035898. 
  3. Dasari SK, Joseph R, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AK.Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. Int J Mol Sci. 2023 Feb 15;24(4). doi: 10.3390/ijms24043915. PubMed PMID: 36835335; PubMed Central PMCID: PMC9962847. 
  4. Zhao S, Li J, Zhang H, Qi L, Du Y, Kogiso M, Braun FK, Xiao S, Huang Y, Li J, Teo WY, Lindsay H, Baxter P, Su JMF, Adesina A, Laczik M, Genevini P, Veillard AC, Schvartzman S, Berguet G, Ding SR, Du L, Stephan C, Yang J, Davies PJA, Lu X, Chintagumpala M, Parsons DW, Perlaky L, Xia YF, Man TK, Huang Y, Sun D, Li XN.Publisher Correction: Epigenetic alterations of repeated relapses in patient-matched childhood ependymomas. Nat Commun. 2022 Dec 22;13(1):7871. doi: 10.1038/s41467-022-35539-0. PubMed PMID: 36550163; PubMed Central PMCID: PMC9780217. 
  5. Abdulkareem NM, Bhat R, Powell RT, Chikermane S, Yande S, Trinh L, Abdelnasser HY, Tabassum M, Ruiz A, Sobieski M, Nguyen ND, Park JH, Johnson CA, Kaipparettu BA, Bond RA, Johnson M, Stephan C, Trivedi MV. Screening of GPCR drugs for repurposing in breast cancer. Front Pharmacol. 2022;13:1049640. doi: 10.3389/fphar.2022.1049640. eCollection 2022. PubMed PMID: 36561339; PubMed Central PMCID: PMC9763283. 
  6. Zhao S, Li J, Zhang H, Qi L, Du Y, Kogiso M, Braun FK, Xiao S, Huang Y, Li J, Teo WY, Lindsay H, Baxter P, Su JMF, Adesina A, Laczik M, Genevini P, Veillard AC, Schvartzman S, Berguet G, Ding SR, Du L, Stephan C, Yang J, Davies PJA, Lu X, Chintagumpala M, Parsons DW, Perlaky L, Xia YF, Man TK, Huang Y, Sun D, Li XN.Epigenetic Alterations of Repeated Relapses in Patient-matched Childhood Ependymomas. Nat Commun.2022 Nov 5;13(1):6689. doi: 10.1038/s41467-022-34514-z. PubMed PMID: 36335125; PubMed Central PMCID: PMC9637194. 
  7. Ghosh S, Mazumdar T, Xu W, Powell RT, Stephan C, Shen L, Shah PA, Pickering CR, Myers JN, Wang J, Frederick MJ, Johnson FM. Combined TRIP13 and Aurora Kinase Inhibition Induces Apoptosis in Human Papillomavirus-Driven Cancers. Clin Cancer Res. 2022 Oct 14;28(20):4479-4493. doi: 10.1158/1078-0432.CCR-22-1627. PubMed PMID: 35972731; PubMed Central PMCID: PMC9588713. 
  8. Rusyn I, Sakolish C, Kato Y, Stephan C, Vergara L, Hewitt P, Bhaskaran V, Davis M, Hardwick RN, Ferguson SS, Stanko JP, Bajaj P, Adkins K, Sipes NS, Hunter ES, Baltazar MT, Carmichael PL, Sadh K, Becker RA.Microphysiological Systems Evaluation: Experience of TEX-VAL Tissue Chip Testing Consortium. Toxicol Sci. 2022 Jul 28;188(2):143-152. doi: 10.1093/toxsci/kfac061. PubMed PMID: 35689632; PubMed Central PMCID: PMC9333404. 
  9. Powell RT, Moussalli MJ, Guo L, Bae G, Singh P, Stephan C, Shureiqi I, Davies PJ. deepOrganoid: A brightfield cell viability model for screening matrix-embedded organoids. SLAS Discov. 2022 Apr;27(3):175-184. doi: 10.1016/j.slasd.2022.03.004. Epub 2022 Mar 18. PubMed PMID: 35314378. 
  10. de Groot E, Varghese S, Tan L, Knighton B, Sobieski M, Nguyen N, Park YS, Powell R, Lorenzi PL, Zheng B, Stephan C, Gopal YNV. Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas. Cancer Metab. 2022 Feb 22;10(1):6. doi: 10.1186/s40170-022-00281-0. PubMed PMID: 35193687; PubMed Central PMCID: PMC8862475. 
  11. Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim M, Umamaheswaran S, Glassman D, Wen Y, Amero P, Stephan C, Coleman RL, Landesman Y, Westin SN, Ram PT, Sood AK. Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Mol Cancer Ther. 2021 Dec;20(12):2352-2361. doi: 10.1158/1535-7163.MCT-21-0370. Epub 2021 Sep 28. PubMed PMID: 34583979; PubMed Central PMCID: PMC8643313.